Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12484810 | 1.00 | OPRM1 (0.44) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL12483541 | 1.00 | OPRM1 (0.44) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL11291105 | 1.00 | OPRM1 (0.44) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL3891492 | 0.97 | OPRM1 (0.46) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL55980 | 0.90 | — | — | |
| SCHEMBL4663784 | 0.83 | TSHR (0.42) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL9014021 | 0.83 | TSHR (0.42) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL4037962 | 0.83 | TSHR (0.42) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL13279660 | 0.83 | TSHR (0.42) | OPRM1ADH1BADH1CADH1AADH4 | |
| SCHEMBL17336107 | 0.83 | TSHR (0.42) | OPRM1ADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157360-B1 | TCDTA-DERIVED FE(III) COMPLEXES FOR USE IN MAGNET RESONANCE IMAGING WITH LIVER AND KIDNEY EXCRETION | UNIV BERLIN CHARITE (DE) | 2024-02-28 | — | — | EP | disclosed |
| CN-116685409-A | Method for flotation of silicate-containing iron ore | 巴斯夫欧洲公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-4011859-B1 | METHOD FOR CHEMICAL STORAGE OF HYDROGEN | APEX ENERGY TETEROW GMBH (DE) | 2023-08-30 | — | — | EP | disclosed |
| CN-116669858-A | Method for flotation of silicate-containing iron ore | 巴斯夫欧洲公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2023151775-A1 | A PROCESS FOR REVERSIBLE HYDROGEN STORAGE VIA AMINO ACID FORMATE ION PAIRS BY HYDROGENATION OF CARBON DIOXIDE | APEX ENERGY TETEROW GMBH (DE) | 2023-08-17 | — | — | WO | disclosed |
| EP-4045095-B1 | IRON (III) COMPLEXES WITH NOVEL CONTRAST PROPERTIES FOR MAGNETIC RESONANCE IMAGING | UNIV BERLIN CHARITE (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-4157360-A1 | TCDTA-DERIVED FE(III) COMPLEXES FOR USE IN MAGNET RESONANCE IMAGING WITH LIVER AND KIDNEY EXCRETION | Charité - Universitätsmedizin Berlin (DE) | 2023-04-05 | — | — | EP | disclosed |
| US-20220331454-A1 | IRON(III) COMPLEXES HAVING NEW CONTRAST AGENT PROPERTIES, FOR MAGNETIC RESONANCE IMAGING | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2022-10-20 | — | — | US | disclosed |
| EP-4045095-A1 | IRON(III) COMPLEXES HAVING NEW CONTRAST AGENT PROPERTIES, FOR MAGNETIC RESONANCE IMAGING | Charité - Universitätsmedizin Berlin (DE) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022122522-A1 | METHOD AND SYSTEM FOR CHEMICAL STORAGE OF HYDROGEN | APEX ENERGY TETEROW GMBH (DE) | 2022-06-16 | — | — | WO | disclosed |
| US-20140024741-A1 | HIGH-LATENCY HARDENERS FOR EPOXY RESINS | ALZCHEM AG (DE) | 2014-01-23 | — | — | US | disclosed |
| US-20130323429-A1 | NOVEL CURING AGENTS FOR EPOXY RESINS | ALZCHEM AG (DE) | 2013-12-05 | — | — | US | disclosed |
| CN-103261263-A | Novel curing agents for epoxy resins | ALZCHEM AG | 2013-08-21 | — | — | CN | disclosed |
| WO-2012113878-A1 | HIGH-LATENCY HARDENERS FOR EPOXY RESINS | ALZCHEM AG (DE) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012113879-A1 | NOVEL CURING AGENTS FOR EPOXY RESINS | ALZCHEM AG (DE) | 2012-08-30 | — | — | WO | disclosed |
| US-20090149584-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF AKTIENGESELLSCHAFT (DE) | 2009-06-11 | — | — | US | disclosed |
| CN-101426843-A | Use of hexahydrophthalimide combinations as softener | BASF SE (DE) | 2009-05-06 | — | — | CN | disclosed |
| EP-2013278-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF SE (DE) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008006834-A2 | USE OF IMIDAZOLE COMPOUNDS AS PLASTICISERS | BASF SE (DE) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007122204-A1 | USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER | BASF SE (DE) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331454-A1 | IRON(III) COMPLEXES HAVING NEW CONTRAST AGENT PROPERTIES, FOR MAGNETIC RESONANCE IMAGING | TFRC, SLC40A1, FTH1 | OPRM1 1629/4885ADH1B 3539/4885ADH1C 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.